Results of a phase I dose escalation and expansion study of tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumor Meeting Abstract
| Authors: | Cranmer, L. D.; Razak, A. R. A.; Ratan, R.; Choy, E.; George, S.; Liebner, D. A.; Stenehjem, D. D.; Gounder, M. M. |
| Abstract Title: | Results of a phase I dose escalation and expansion study of tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumor |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300365 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.11523 |
| Notes: | Meeting Abstract: 11523 -- This meeting was also held virtually -- Source: Wos |
